Phreesia (NYSE:PHR) Price Target Cut to $25.00 by Analysts at Citigroup

Phreesia (NYSE:PHR) had its price objective lowered by Citigroup from $29.00 to $25.00 in a research note published on Friday,Benzinga reports. Citigroup currently has a buy rating on the stock.

A number of other analysts have also recently issued reports on the stock. Canaccord Genuity Group reduced their target price on shares of Phreesia from $38.00 to $33.00 and set a “buy” rating for the company in a research note on Tuesday, December 9th. Royal Bank Of Canada began coverage on shares of Phreesia in a report on Friday. They set an “outperform” rating and a $26.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Phreesia in a research note on Monday, December 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Phreesia in a research report on Friday, October 31st. Finally, Robert W. Baird cut their target price on Phreesia from $31.00 to $25.00 and set an “outperform” rating on the stock in a report on Wednesday, December 10th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $30.06.

Phreesia Stock Performance

Shares of NYSE PHR opened at $17.24 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.44 and a quick ratio of 2.44. Phreesia has a one year low of $15.41 and a one year high of $32.76. The business’s 50-day moving average price is $18.95 and its two-hundred day moving average price is $23.75. The company has a market capitalization of $1.04 billion, a P/E ratio of -172.37 and a beta of 0.61.

Phreesia (NYSE:PHR) last announced its quarterly earnings results on Monday, December 8th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.11. The business had revenue of $120.33 million during the quarter, compared to analyst estimates of $119.98 million. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.The firm’s revenue was up 12.7% on a year-over-year basis. During the same period in the previous year, the company earned ($0.25) EPS. Analysts anticipate that Phreesia will post -1.1 earnings per share for the current fiscal year.

Insider Transactions at Phreesia

In other Phreesia news, General Counsel Allison C. Hoffman sold 1,241 shares of the stock in a transaction on Friday, October 17th. The shares were sold at an average price of $22.36, for a total value of $27,748.76. Following the completion of the sale, the general counsel directly owned 135,737 shares of the company’s stock, valued at $3,035,079.32. This represents a 0.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Evan Roberts sold 1,888 shares of Phreesia stock in a transaction dated Friday, October 17th. The stock was sold at an average price of $22.36, for a total value of $42,215.68. Following the sale, the insider directly owned 724,949 shares in the company, valued at approximately $16,209,859.64. This trade represents a 0.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 7,534 shares of company stock worth $165,514. Company insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Phreesia

Institutional investors have recently bought and sold shares of the business. Royal Bank of Canada boosted its holdings in Phreesia by 208.8% during the first quarter. Royal Bank of Canada now owns 24,119 shares of the company’s stock valued at $617,000 after purchasing an additional 16,309 shares in the last quarter. AQR Capital Management LLC grew its holdings in Phreesia by 471.2% during the 1st quarter. AQR Capital Management LLC now owns 160,032 shares of the company’s stock worth $4,090,000 after acquiring an additional 132,015 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Phreesia by 3.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,557 shares of the company’s stock worth $1,599,000 after acquiring an additional 2,158 shares during the last quarter. NewEdge Advisors LLC lifted its position in shares of Phreesia by 262.7% during the first quarter. NewEdge Advisors LLC now owns 15,437 shares of the company’s stock worth $395,000 after purchasing an additional 11,181 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in shares of Phreesia by 0.4% during the first quarter. Goldman Sachs Group Inc. now owns 600,012 shares of the company’s stock valued at $15,336,000 after purchasing an additional 2,402 shares during the last quarter. Institutional investors and hedge funds own 92.10% of the company’s stock.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.